Moderna, Inc. (MRNA) shares plunged 5.05% in pre-market trading on Thursday, following a significant price target cut by RBC Capital Markets. The investment bank lowered its target for Moderna from $40 to $32, while maintaining a Sector Perform rating on the stock.
The dramatic reduction in price target reflects growing concerns about Moderna's near-term prospects. This move by RBC aligns with the overall cautious sentiment among analysts, as FactSet reports that Moderna currently has an average rating of "hold" with a mean price target of $50.35.
The biotech company, known for its mRNA technology and COVID-19 vaccine, has been facing challenges as demand for coronavirus vaccines wanes. Investors are closely watching Moderna's pipeline and its ability to leverage its technology platform for other therapeutic areas. The sharp stock decline suggests that the market is adjusting its expectations for Moderna's future performance in light of the lowered price target.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。